Description:
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid
tumors or relapsed refractory metastatic breast cancer (patients with progressive disease
after receiving at least two lines of therapy in the advanced setting).
Title
- Brief Title: ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
- Official Title: A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects With Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
ORIN1001-001
- NCT ID:
NCT03950570
Conditions
- Advanced Solid Tumor
- Metastatic Breast Cancer
Interventions
Drug | Synonyms | Arms |
---|
Abraxane | ORIN1001 | Phase 1: Dose Escalation |
Purpose
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid
tumors or relapsed refractory metastatic breast cancer (patients with progressive disease
after receiving at least two lines of therapy in the advanced setting).
Detailed Description
This is a first in human, Phase 1/2, open label, dose escalation and dose expansion study
that consists of two stages:
Phase 1: A dose escalation stage to determine the MTD/RP2D of ORIN1001 when given as a single
agent in up to 30 subjects with advanced solid tumors. In addition, a dose escalation stage
to determine the MTD/RP2D of daily ORIN1001 in combination with Abraxane given intravenously
in up to 18 subjects with relapsed refractory metastatic breast cancer (TNBC or ER+ HER2-).
Phase 2: An expansion stage of ORIN1001 alone (Cohort A: TNBC) and in combination with
Abraxane (Cohort B: Myc+; Cohort C: ER+ HER2-, and Cohort D: TNBC) to estimate efficacy in up
to 120 subjects with relapsed refractory metastatic breast cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
Phase 1: Dose Escalation | Experimental | Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.
Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and Abraxane. | |
Phase 2: Dose Expansion | Experimental | Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination with ORIN1001 and Abraxane. | |
Eligibility Criteria
Inclusion Criteria:
For dose escalation with ORIN1001 alone:
-Male or female with advanced solid tumors for which no effective standard of care
treatments are available
For dose escalation with ORIN1001 in combination with Abraxane:
-Males or females with relapsed refractory metastatic breast cancer (TNBC or ER+, HER2-)
must have progressed through at least 2 lines of therapy and for whom there are no
available therapies that confer a clinical benefit
For dose expansion:
a. Males or females with relapsed refractory metastatic breast cancer including:
1. TNBC (i.e. estrogen receptor (ER)-, progesterone receptor-, and human epidermal growth
factor receptor 2 [HER2]-)
2. ER+ HER2- breast cancer
Inclusion Criteria for Dose Escalation and Dose Expansion
1. Adults aged ≥ 18 years
2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
3. Life expectancy of 3-4 months
4. Have at least one measurable lesion per RECIST 1.1
5. Have adequate organ function, including all of the following:
1. Adequate bone marrow reserve as defined by: ANC≥1.0 x 10 9/L; platelet count ≥75
x 10 9/L; hemoglobin ≥9 g/dL
2. Hepatic: total bilirubin ≤2 x ULN, transaminases (AST/SGOT and/or ALT/SGPT) ≤ 3X
ULN;alkaline phosphatase ≤ 5 x ULN
3. Renal: 24-hour creatinine clearance ≥ 30 mL/min calculated
6. Adequate tissue sample from either archival tumor tissue or fresh biopsy of tumor at
the screening for tumor genotyping.
7. Male subjects must be surgically sterile or must agree to use physician approved
contraception for 7 days prior to the first study drug administration to 30 days after
the last dose of study treatment.
8. Women of childbearing potential must have negative serum pregnancy test within 14 days
prior the first administration of study drug and agree to use physician-approved
contraception from 30 days prior to the first study drug administration to 30 days
following the last study drug administration.
9. Ability to understand and willingness to sign an informed consent prior to any study
specific procedures.
10. Resolution of all toxicities (except alopecia) from prior therapy to ≤ Grade 1 (CTCAE
v5)
Exclusion Criteria:
1. Does not meet inclusion criteria
2. Received any of the following within the specified time frame prior to the first
administration of study drug:
i. Excluding those with a history of coagulopathy ii. Excluding those who require
concurrent use of anti-coagulants or anti-platelet medication, with exception of
aspirin doses ≤ 81 mg/day, prophylaxis subcutaneous (SC) heparin or SC low-molecular
weight heparin for deep vein thrombosis (DVT) prophylaxis or heparin flushes to
maintain IV catherer patency iii. Excluding subjects that have Prothrombin time
(PT)/international normalized ratio (INR) or activated partial thromboplastin time
(aPTT) >1.5 x ULN b.Prior chemotherapy or other systemic anticancer therapy within 3
weeks or 5 times the plasma half-life of the drug, whichever is shorter; c.Prior
radiotherapy within 2 weeks; d.Major surgery within 2 weeks; e.Prior treatment with
investigational drugs within 4 weeks; f. Myocardial infarction, uncontrolled
angina,severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
of acute ischemia, within 6 months prior to the fist dose of study drug
3. Greater than Class II heart failure using New York Heart Association (NYHA) criteria
4. The subject has uncontrolled human immunodeficiency virus (HIV) infection or active
hepatitis B or C infection or other known active and/or uncontrolled infection
5. Active autoimmune disease that is not appropriately controlled with treatment
6. Active malignancy with the exception of:
1. adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ
cervical cancer
2. adequately treated stage I cancer from which the subject is currently in
remission, or
3. any other cancer from which the subject has been disease-free for ≥3 years;
7. Any serious uncontrolled medical or psychological disorder that would impair the
ability to receive protocol therapy
8. Any condition which places the subject at unacceptable risk or confounds the ability
of the investigator to interpret study data
9. The subject is pregnant or lactating woman. Any woman who becomes pregnant during the
study will be withdrawn from the study.
10. Known active uncontrolled or symptomatic brain metastases. Patients with a history of
such metastases that have been treated and are stable ≥28 days may be enrolled.
Patients with no steroid use for at least 2 weeks prior to the time of enrollment are
permitted.
11. Failed to respond to the most recent dose of Abraxane and must have been received at
least 12 months prior to starting treatment.(combination arm only)
12. Greater than Grade 1 neuropathy (combination arm only)
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors: NCI CTCAEv5 Common Toxicity Criteria |
Time Frame: | From first dose up to 21 days after last dose |
Safety Issue: | |
Description: | To determine the safety of the maximal tolerated dose/ recommended Phase 2 dose (MTD/RP2D). Incidence of the safety population will consist of all subjects who received a dose of study drug. Treatment-related AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. Adverse events will be evaluated and recorded according to NCI CTCAEv5 Common Toxicity Criteria and will use medical terminology based on the Medical Dictionary for Regulatory Activities Terminology (MedDRA). |
Secondary Outcome Measures
Measure: | To evaluate the peak concentrations (Cmax) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent peak concentrations (Cmax) of ORIN1001 by direct inspection of the plasma concentration-time curves of ORIN1001 following single and repeat oral doses of ORIN 1001 as a single agent and in combination with Abraxane. |
Measure: | To evaluate the time to peak concentrations (Tmax) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent time to peak concentrations (Tmax) of ORIN1001 by direct inspection of the plasma concentration-time curves of ORIN1001 following single and repeat oral doses of ORIN 1001 as a single agent and in combination with Abraxane. |
Measure: | To evaluate the area under the plasma concentration versus time curve (AUC) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent area under the plasma concentration versus time curve (AUC) for ORIN1001 following single doses of ORIN 1001 as a single agent and in combination with Abraxane. |
Measure: | To evaluate the last time point with a quantifiable concentration (AUClast) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent plasma levels of ORIN1001 from the time of dosing to the last time point with a quantifiable concentration (AUClast) of ORIN1001 following single doses of ORIN 1001 as a single agent and in combination with Abraxane. |
Measure: | To evaluate the plasma concentration end of a dosing interval (Ctau) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent plasma concentrations (Cmax) of ORIN1001 as single agent or in combination with Abraxane at the end of a dosing interval (Ctau), where tau is 24 hours for once daily dosing. |
Measure: | To evaluate the average plasma concentration (Cav) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the average plasma concentration (Cav) of ORIN1001 as single agent or in combination with Abraxane during the dosing interval. |
Measure: | To evaluate the minimum plasma concentrations (Cmin) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the the minimum plasma concentrations (Cmin) reached by ORIN1001 as single agent or in combination with Abraxane prior to administration of a second dose. |
Measure: | To evaluate the elimination constant (λz) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent plasma elimination constant (λz) for ORIN1001 as a single agent or in combination with Abraxane. |
Measure: | To evaluate the terminal half-life (T1/2) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent terminal plasma half-life of ORIN1001 (T1/2) as a single agent or in combination with Abraxane. |
Measure: | To evaluate the plasma clearance (CL/f) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the dose-dependent apparent total plasma clearance (CL/f) of ORIN1001 after oral administration as a single agent or in combination with Abraxane. |
Measure: | To evaluate the volume of distribution (Vz/f) of ORIN1001 after oral administration as a single agent and in combination with Abraxane. |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Determine the apparent volume of distribution (Vz/f) during terminal phase after oral administration of ORIN1001 as a single agent or in combination with Abraxane. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Orinove, Inc. |
Trial Keywords
- Solid tumors, Breast Cancer
Last Updated
August 10, 2021